Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of TAK-438 for the Prevention of Recurrent Gastric or Duodenal Ulcers During Therapy of Non-steroidal Anti-inflammatory Drug (NSAID)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Participants who require continuous NSAID therapy during the treatment period with the study drug~2. Participants who have a history of ulcer in stomach or duodenum, endoscopically confirmed~3. Outpatient (including inpatient for examinations)~Exclusion Criteria:~1. Participants scheduled to change the type and dosage regimen of NSAID~2. Participants with ulcers or bleeding in stomach or duodenum, endoscopically confirmed~3. Participants with small intestine bleeding, large intestine bleeding, or gastrointestinal bleeding of unknown etiology~4. Participants who have a history of surgery which affects gastric acid secretion (e.g., resection of upper gastrointestinal tract, vagotomy) or who are scheduled to undergo such surgery~5. Participants with a previous or current history of Zollinger-Ellison syndrome, or other gastric acid hypersecretion disorders~6. Participants with a previous or current history of aspirin-induced asthma

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- TAK-438 10 mg QD (Type: EXPERIMENTAL): None
- TAK-438 20 mg QD (Type: EXPERIMENTAL): None
- Lansoprazole 15 mg QD (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).